

Oxidant-Dependent Chemoselectivity in the Gold-Catalyzed Oxidative Cyclizations of 3,4,6,6-Tetrasubstituted 3,5-Dien-1-ynes

Hsiao-Hua Hung, Yi-Ching Liao, and Rai-Shung Liu*

Department of Chemistry, National Tsing-Hua University, Hsinchu, Taiwan, ROC

Supporting Information

ABSTRACT: A distinct chemoselectivity in the gold-catalyzed oxidative cyclization of 3,5-dien-1-ynes was observed when 3,5dichloropyridine N-oxide replaced 8-methylquinoline N-oxide as the oxidant; the resulting cyclopentadienyl aldehydes were obtained in good yields. The altered chemoselectivity is attributed to a prior enyne cyclization in the presence of 3,5dichloropyridine N-oxides. The use of N-iminopyridium ylide

enables a similar iminocyclization reaction to give cyclopentadienyl imines efficiently. Our experimental data support a prior goldcatalyzed cyclization of 3,5-dien-1-ynes to form gold carbene, followed by the oxidation with N-oxide.

■ INTRODUCTION

Gold-catalyzed intermolecular oxidation of terminal alkynes with pyridine-based oxides is a powerful tool to access α functionalized carbonyl compounds (eq 1).¹⁻³ This oxidation

involves an initial attack of N-oxides at the alkynyl C(2)-carbon to generate α -oxo gold carbenes I that are trapped in situ with a suitable substrate (S).^{1,2} The chemoselectivity in this alkyne oxidation is generally invariant with diverse derivatives of pyridine-based oxides. We are aware of no report in which the reaction chemoselectivity varied with a change of N-oxide. In this work, we report a distinct chemoselectivity in the oxidative cyclization of 3,5-dien-1-ynes with alterable pyridine-based Noxides.

Shown in Scheme 1 is the oxidant-dependent chemoselectivity. We reported that gold-catalyzed reactions between

Scheme 1. Two Distinct Oxidative Cyclizations

Previous report:

This work

 $[Au] = IPrAuCl/AgNTf_2$

3,5-dien-1-ynes and 8-methylquinoline N-oxide (8-MQO) resulted in an oxidative cyclopropanation with high stereospecificity; 2b this process involves α -oxo gold carbenes as intermediates.^{1,2} Herein, we report the use of 3,5-dichloropyridine N-oxide in the reactions to give cyclopentadienyl aldehydes 3 instead and present experimental results to clarify the reaction mechanisms.

RESULTS AND DISCUSSION

Table 1 (entry 1) shows our previously reported reaction between dienyne 1a, IPrAuCl/AgNTf₂ (5 mol %, IPr = 1,3bis(diisopropylphenyl)imidazol-2-ylidene), and 8-methylquinoline N-oxide (8-MQO, 1.2 equiv) in hot DCE (80 °C, 0.33 h), resulting in an oxidative cyclopropanation product 2a in 60% yield. 2b The yield was increased to 78% using the same Noxidant in a large proportion (3 equiv). We tested the reactions with alterable pyridine-based N-oxides; Brønsted acids were excluded here to avoid the polymerization of starting 1a. With pyridine N-oxide and its 2-ethyl derivative (1.2 equiv) in hot DCE (80 °C, 24-48 h), we obtained a new compound, cyclopentadienyl aldehyde 3a, in low yield (<35%) together with indanone 2a and unreacted 1a in a substantial proportions (>18%, entries 2 and 3). The yields of aldehyde 3a were enhanced to 56-60% yields with electron-deficient pyridine Noxides bearing a chloro or bromo substituent at the C(2)- or C(3)-carbons (entries 4-6). To our pleasure, the use of 3,5dichloropyridine N-oxide in hot DCE (80 °C, 0.33 h) effected a complete suppression of cyclopropyl indanone 2a to deliver compound 3a with 83% yield (entry 7). IPrAuCl/AgSbF₆ also maintained a high efficiency to give aldehyde 3a in 76% yield (entry 9). P(t-Bu)₂(o-biphenyl)AuCl/AgNTf₂ and PPh₃AuCl/ AgNTf₂ were less chemoselective in giving compound 3a in less yield together with undesired 2a in 16-22% yields (entries 10

Received: May 28, 2013



Table 1. Reactions with Various N-Oxides and Gold Catalysts

					с	
entry	catalyst ^a (mol %)	N-oxide ^b	°C/h	la	2a	3a
1	IPrAuCl/AgNTf ₂	8-MQO	80/0.3		$60 (78)^d$	
2	IPrAuCl/AgNTf ₂	R = H	80/48	59	24	6
3	IPrAuC1/AgNTf ₂	R = 2-Et	80/24	25	35	18
4	IPrAuCl/AgNTf ₂	R = 2-Br	80/0.7		24	60
5	$IPrAuCVAgNTf_2$	R = 3-Br	80/0.2		26	57
6	${\rm IPrAuCyAgNTf}_2$	R = 2-C1	80/0.3		30	56
7	IPrAuCl/AgNTf ₂	$R = 3.5 - Cl_2$	80/0.3			83
8	$IPrAuCVAgNTf_2$	$R = 3.5 - Cl_2$	25/0.6			81
9	IPrAuCl/AgSbF ₆	$R = 3.5 - Cl_2$	25/0.8			76
10	LAuCl/AgNTf ₂	$R = 3.5 - Cl_2$	25/1.0		22	57
11	PPh ₃ AuCl/AgNTf ₂	$R = 3.5 - Cl_2$	25/1.2		16	56
12	Ph ₂ SO	Ph ₂ SO	25/0.5			e

"8-MQO = 8-methylquinoline N-oxide, IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, $L = P(t-Bu)_2(o$ -biphenyl), [\mathbf{la}] = 0.05 M. bN -Oxide (1.2 equiv). Product yields are reported after separation on a silica column. dT his value corresponds to 8-MQO with 3.0 equiv. Polymerization of starting \mathbf{la} was observed.

and 11). We tested the reaction with Ph_2SO (1.2 equiv),⁴ which led to a polymerization of starting Ia (entry 12); the same polymerization was observed in the absence of oxides, reflecting the sensitivity of starting Ia toward an acidic gold catalyst. Only basic N-oxides can reduce the acidity of $IPrAuNTf_2$ to secure the stability of starting Ia.

Table 2 shows the gold-catalyzed reactions between various 3,5-dien-ynes 1b-1j with 3,5-dichloropyridine N-oxide, giving only cyclopentadienyl aldehydes 3b-3j, whereas competitive cyclopropyl indanones 2 were completely suppressed. In entries 1 and 4, starting 1b was prepared as a mixture of E/Z isomers (E/Z = 1.4), whereas species 1e was prepared as the E-isomer. Entries 1-4 show the applicability of this new oxidative

Table 2. Oxidative Cyclization with Various 3,5-Dien-1-ynes^a

^aIPr = 1,3-bis(2,6-dii8opropylphenyl)imidazol-2-ylidene, L = $P(t-Bu)_2(o-biphenyl)$, [Ia] = 0.05 M, N-oxide (1.2 equiv). Product yields are reported after separation on a silica column. 1b, E/Z = 1.4. 1e is E-isomer.

cyclization to 3,5-dien-1-ynes **1b–1e** bearing various substituted alkenes; the resulting aldehydes **3b–3d** were obtained in satisfactory yields (60–75%) with the exception of compound **3e** that was obtained in a low yield (39%). We tested the reactions on 3,5-dien-1-ynes **1f–1h** bearing a substituted cyclohexenyl bridge; the corresponding products **3f–3h** were produced with 54–69% yields. This reaction was applicable also to substrate **1i** bearing a cycloheptenyl bridge, giving desired product **3i** in 80% yield. For an acyclic 3,5-dien-1-yne **1j**, its gold-catalyzed reaction delivered cyclopentadienyl aldehyde **3j** in 68% yield. Our attempted reaction on 3,5-dien-1-yne bearing a single phenyl substituent in the 6-position, unlike compound **1e**, gave a complicated mixture of products. §

We examined the reaction of a benzenoid substrate 4 with 3,5-dichloropyridine N-oxide, which delivered cyclopropyl indanone 5 instead (eq 1). The same reaction pattern was observed using N-iminopyridium ylide^{6,7} to afford cyclopropyl indanimine 6 in 80% yield (eq 2), whereas for non-benzenoid

3,5-dien-1-yne 1a, a different chemoselectivity occurred to give cyclopentadienyl imine 7a in 84% yield (eq 3). NaBH₃CN-reduction of imine species 7a provided primary imine 8a in 67% yield, which was characterized by X-ray diffraction (eq 3).

Table 3 shows the gold-catalyzed synthesis of cyclopentadienyl imines from the same 3,5-dien-1-ynes **1b-1j** as in Table 2. The reaction proceeded with high chemoselectivity to afford cyclopentadienyl imines **7b-7j** exclusively. For 3,5-dien-1-ynes **1b-1e** bearing various trisubstituted alkenes, their resulting cyclopentadienyl imines **7b-7e** were produced in **57-76%** yields (entries **1-4**). This iminocyclization was operable with additional 3,5-dien-1-ynes **1f-1h** bearing a varied cyclohexenyl bridge, giving desired imines **7f-7h** with **66-**

Table 3. Scope for Gold-Catalyzed Iminocyclizations^a

"IPr = l,3-bis(2,6-diisopropylphenyl)imidazol-2-ylideiie, L = P(t-Bu) $_2(o$ -biphenyl), [la] = 0.05 M. N-oxide (1.2 equiv). Product yields are reported after separation on a silica column. 1b, E/Z = 1.4. 1e, E/Z = 1.0.

72% yields (entries 5–7). The reaction worked also with substrate 1i bearing a cycloheptenyl bridge, giving the corresponding product 7i in 75% yield (entry 8). Acyclic 3,5-dien-1-yne 1j was also suitable for this iminocyclization, giving desired 7j in 72% yield (entry 9).

As shown in Scheme 2, we performed a reaction with 8-methylquinoline *N*-oxide and 3,5-dichloropyridine *N*-oxide in

Scheme 2. Oxidation Properties of N-Oxides

equal proportions ((3,5-DCPO, 1.5 equiv, Scheme 2) and obtained desired cyclopropyl indanone 2a together with a new product 9 in 33% and 39% yields respectively; cyclopentadienyl aldehyde 3a was obtained in a negligible proportion. Pyranyl aldehyde 9 was generated with $6-\pi$ electrocyclization of α -carbonyl aldehyde 9' that resulted from a second oxidation of gold carbenes C (*vide ante*, Scheme 4). Compound 3a were generated in 15% yield with a decreasing loading of 8-methylquinoline N-oxide (1.1 equiv, entry 2). These data provide insight into the effects of two N-oxides, namely, that 8-methylquinoline N-oxide is more active than 3,5-dichloropyr-

idine N-oxide for the alkyne oxidation and is inactive toward the carbene oxidation.

Scheme 3 shows the deuterium labeling experiments. The treatment of deuterated d_1 -1a with 3-bromopyridine N-oxide

Scheme 3. Deuterium Labeling Experiments

(1.1 equiv) in DCE at 28 °C (0.5 h) led to a 80% conversion, giving unreacted d_1 -1a and cyclopropyl indanone d_1 -2a and cyclopentadienyl aldehyde d_1 -3a in 16%, 24%, and 54% recovery or yields, respectively. Notably, the deuterium contents X, Y, and Z are nearly the same (40–42%). Alternatively, the use of undeuterated 1a and D_2O (1.0 equiv) in this reaction also provided deuterated d_1 -2a and d_1 -3a with the same level of deuterium contents (58–60%). These results indicates that the loss of deuterium content of d_1 -2a and d_1 -3a is attributed to a quick equilibrium between π -alkyne A and alkynyl gold B (Scheme 4). This A/B equilibrium allows a quick change between d_1 -1a and water before the production of d_1 -2a and d_1 -3a.

Scheme 4 depicts possible mechanisms to rationalize the formation of cyclopropyl indanone 2a and cyclopentadienyl

Scheme 4. Possible Reaction Mechanisms

aldehyde 3a; the latter was produced with less nucleophlic N-oxides that attack π -alkyne A inefficiently. The deuterium labeling experiments in Scheme 3 indicate that an equilibrium 10,11 between π -alkyne A and alkynylgold species B is rapidly attained before products 2a and 3a are formed. N-Oxides are reported to catalyze this A/B equibrium. 10

Besides a prior cyclization route (path a) involving the transformation π -alkyne $A \to \text{gold}$ carbene C, a small portion of species B might undergo protonation at the dienyl C(3)-carbon to give an allylic cation D (path b), which induces a cyclization to generate gold allenylidene E, ultimately giving gold carbene C. We sought suitable experiments to probe the feasibility of the two paths (a and b).

We assessed the role of alkynylgold intermediate B to participate the alkyne oxidation, as depicted in path b. As depicted in Table 4, we prepared alkynylgold species 10^{12} and

Table 4. Alkynylgold Species as the Catalysts^a

entry	oxidant	mol % HNTf ₂	min	yield ^b
1	Z = NTs	1.0	20	7a (86%)
2	Z = NTs	0	600	7a (56%)
3	Z = O	1.0	120	3a (75%)
4	Z = O	0	600	1a (55%)

^a[1a] = 0.05 M. N-oxide (1.2 equiv). ^bProduct yields are reported after separation on a silica column.

used it as a catalyst (5 mol %) in both oxidation and nitrene reactions. In the nitrene reaction, we obtained excellent yields (86%) for desired product 7a with $HNTf_2$ (1 mol %). To our surprise, the catalytic reaction still proceeded in the absence of $HNTf_2$ to give compound 7a in 56% yield over a protracted period (10 h, entry 2). In contrast, $HNTf_2$ was required for the oxidation reactions using alkynylgold 10 catalyst (entries 3 and 4).

To understand the role of alkynylgold species B in path b, we performed a control experiment in eq 4, involving Ia (1 equiv),

N-iminopyridium ylide (1 equiv) and alkynylgold species 11 (0.15 equiv). Heating this mixture in hot DCE for a brief period (1 h) gave no desired iminocyclization products 7a and 7f, but we obtained a mixture of 3,5-dien-1-ynes 1a and 1f with a 1a/1f ratio of 7.7/1. Accordingly, alkynylgold species B preferably underwent protonation to produce gold- π -alkyne species A, rather than giving gold-vinylidene E, thus excluding the route b in Scheme 4. Herein, N-iminopyridium ylide serves as a proton shuttle with dien-1-yne 1a as the proton source. At a protracted period (16 h), the same reaction gave desired iminocylization products 7a and 7f, albeit in low yields (30–35%); in this case, alkynylamide 12 was obtained in minor proportion (eq 5). This

result reveals that alkynylgold species 11 was a poor catalyst for this iminocyclization; the corresponding mechanism might be different. The isolation of alkynylamide 12 allows us to understand the reaction mechanism in eq 4.

CONCLUSIONS

A distinct chemoselectivity in the gold-catalyzed oxidative cyclization of 3,5-dien-1-ynes occurred when 8-methylquinoline *N*-oxide was replaced with 3,5-dichloropyridine *N*-oxide; the resulting cyclopentadienyl aldehydes were obtained in

satisfactory yields. The change of chemoselectivity is attributed to the weak nucleophilicity of 3,5-dichloropyridine N-oxide such that a prior cyclization of 3,5-dien-1-ynes occurs preferably. The reactions were extensible to their iminocyclizations when the same 3,5-dien-1-ynes were treated with N-iminopyridium ylide. Our experimental results support a prior gold-catalyzed cyclization of 3,5-dien-1-ynes to form gold carbene C, followed by the oxidation with N-oxide. In a case involving alkynylgold as the catalyst, a prior protonation of alkynylgold to give π -alkyne occurred preferably.

EXPERIMENTAL SECTION

General Comments. Unless otherwise noted, all reactions to prepare the substrates were performed in oven-dried glassware under a nitrogen atmosphere with freshly distilled solvents. The catalytic reactions were performed under a nitrogen atmosphere. Toluene, DCE, and methanol were distilled from CaH₂ under nitrogen. Methanol and triethylamine (Et₃N) were stored over molecular sieves (4 Å) before use. All other commercial reagents were used without further purification, unless otherwise indicated. ¹H NMR and ¹³C NMR spectra were recorded on 400 and 600 MHz spectrometers using chloroform- d_1 (CDCl₃), CD₂Cl₂, or DMSO- d_6 as the internal standard. EI/MS-MS, ESI/FTMS, and ESI/orbitrap mass spectrometry were used for the HRMS measurements. All 1,5-enynes (1a–1i) were prepared from the reported procedure in the literature. ¹⁵

General Procedure for Gold-Catalyzed Oxidative Cyclization between 1,5-Enyne (1a) and 3,5-Dichloropyridine *N*-Oxide. A 1,2-dichloroethane solution (4.2 mL) of compound 1a (50 mg, 0.31 mmol) and 3,5-dichloropyridine *N*-oxide (60.7 mg, 0.37 mmol) was added to a 1,2-dichloroethane solution (2.0 mL) of IPrAuNTf₂ (13.9 mg, 0.016 mmol). The mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford 3a as a yellow oil (45.4 mg, 0.26 mmol, 83%).

General Procedure for Gold-Catalyzed Oxidative Cyclization between 1,5-Enyne (1a) and (3,5-Dichloro-pyridinium-1-yl)tosylamide. To a 1,2-dichloroethane solution (4.2 mL) of compound 1a (50 mg, 0.31 mmol) and (3,5-dichloro-pyridinium-1-yl)tosylamide (117.4 mg, 0.37 mmol) was added a 1,2- dichloroethane solution (2.0 mL) of IPrAuNTf₂ (13.9 mg, 0.016 mmol); the mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica column to afford 7a as an orange red oil (85.8 mg, 0.26 mmol, 84%).

Procedure for Gold-Catalyzed Oxidative Cyclization between Deuterated 1-Ethynyl-2-(2-methylprop-1-en-1-yl)-cyclohex-1-ene (d_1 -1a) and 3-Bromo Pyridine N-Oxide. A 1,2-dichloroethane solution (3.7 mL) of compound d_1 -1a (50 mg, 0.31 mmol) and 3-bromopyridine N-oxide (64.4 mg, 0.37 mmol) was added to a 1,2-dichloroethane solution (2.5 mL) of IPrAuNTf₂ (13.8 mg, 0.016 mmol). The mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford compound d_1 -1a as a pale yellow oil (8.0 mg, 0.05 mol, 16%), compound d_1 -2a as a colorless oil (13.2 mg, 0.07 mmol, 24%), and compound d_1 -3a as a yellow oil (29.7 mg, 0.17 mmol, 54%).

Synthesis of N-((2,2-Dimethyl-4,5,6,7-tetrahydro-2H-inden-1-yl)methyl)-4-methylbenzenesulfonamide (8a). To a THF solution (5.2 mL) of compound 7a (86 mg, 0.26 mmol) was added NaBH $_3$ CN (18 mg, 0.26 mmol), and the mixture was stirrred for 4 h at room temperature, quenched with water, and extracted with ethyl acetate (20 mL \times 3). The combined organic layer was dried over anhydrous MgSO $_4$ and concentrated on an evaporator. The residue was eluted through a short pad of silica column to afford compound 8a as pale yellow solid (58 mg, 0.17 mmol, 67%).

Synthesis of 3,3-Dimethyl-5,6,7,8-tetrahydro-3*H*-isochromene-1-carbaldehyde (9). A 1,2-dichloroethane solution (3.7 mL) of compound 1a (50 mg, 0.31 mmol), 8-methylquinoline *N*-oxide (74.8 mg, 0.47 mmol), and 3,5-dichloropyridine *N*-oxide (152.5

mg, 0.93 mmol) was added to a 1,2-dichloroethane solution (2.5 mL) of IPrAuNTf₂ (13.8 mg, 0.016 mmol). The mixture was heated to 80 $^{\circ}$ C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford compound 2a as a pale yellow oil (18 mg, 0.10 mol, 33%), compound 9 as a yellow oil (23.0 mg, 0.12 mmol, 39%), and a trace amount of compound 3a with yellow oil.

Synthesis of 1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (10). A round-bottom flask (10 mL) was charged with 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene gold chloride (76.7 mg, 0.12 mmol) and NaOH (9.6 mg, 0.24 mmol). After the flask was evacuated and refilled with nitrogen, methanol (3.0 mL) was added by syringe, and the reaction mixture was stirred for 20 min. Dichloromethane (1.5 mL) was added until a homogeneous solution was obtained. Compound 1a (20.0 mg, 0.12 mmol) was added directly to this solution. The reaction was covered in foil and stirred for 36 h followed by removal of the volatiles under vacuum and extraction of the residue with benzene (10 mL × 3). After filtration to remove insoluble salts and purification by recrystallization (benzene and pentane), the desired compound 10 was obtained as white solid (61.0 mg, 0.082 mmol, 68%).

Synthesis of 1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((5,5-dimethyl-2-(2-methylprop-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (11). A MeOH solution (4.2 mL) of NaO¹Bu (15.4 mg, 0.16 mmol) and compound 1f (30.0 mg, 0.16 mmol) was stirred for 10 min before addition of a MeOH solution (2.0 mL) of 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene gold chloride (49.7 mg, 0.08 mmol). The reaction was covered in foil and stirred for 48 h followed by removal of the volatiles under vacuum and extraction of the residue with dichloromethane (10 mL × 3). After filtration to remove insoluble salts and purification by recrystallization (benzene and pentane), the desired compound 11 was obtained as a pale yellow solid (84.0 mg, 0.11 mmol, 68%).

Synthesis of (3,5-Dichloropyridin-1-ium-1-yl)((2-(2-methyl-prop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)amide (12). To a 1,2-dichloroethane solution (4.2 mL) of compound 1a (50 mg, 0.31 mmol) and (3,5-dichloro-pyridinium-1-yl)tosylamide (104.7 mg, 0.33 mmol) was added a 1,2-dichloroethane solution (2.0 mL) of compound 11 (36.0 mg, 0.047 mmol); the mixture was heated to 80 °C for 1 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica column to afford compound 1a as a yellow oil (42 mg, 0.26 mmol, 85%), compound 1f as a yellow oil (6.5 mg, 0.034 mmol, 0.11 equiv), and compound 12 as a yellow oil (7.0 mg, 0.022 mmol, 0.07 equiv).

Deuterated 1,1-Dimethyl-1,2,3,4,5,6a-hexahydrocyclo-propa[a]inden-6(1aH)-one (d_1 -2a). Pale yellow oil; (13 mg, 24%); 1 H NMR (400 MHz, CDCl₃) δ 2.40–2.34 (m, 1 H), 2.17–2.11 (m, 2 H), 2.10–2.03 (m, 2 H), 1.92 (d, J = 4.4 Hz, 0.6 H), 1.70–1.61 (m, 3 H), 1.52–1.48 (m, 1 H), 1.17 (s, 3 H), 1.04 (s, 3 H); 13 C NMR (150 MHz, CDCl₃) δ 204.3, 168.8, 137.3, 48.3, 48.2, 38.1, 37.9 (t, J = 26 Hz), 37.3, 37.2, 28.7, 27.2, 27.1, 22.2, 21.7, 19.5, 14.3; HRMS calcd for C_{12} H₁₆O 176.1201, found 176.1197, 177.1262.

2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde **(3a).** Yellow oil; (45 mg, 83%); 1 H NMR (400 MHz, CDCl₃) δ 9.86 (s, 1 H), 6.28 (s, 1 H), 2.86 (t, J = 6.4 Hz, 2 H), 2.47 (td, J = 6.4, 2.0 Hz, 2 H), 1.72–1.59 (m, 4 H), 1.21 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 183.8, 160.6, 151.1, 145.5, 139.3, 51.1, 24.8, 24.0, 22.8, 22.4, 21.8; HRMS calcd for C_{12} H₁₆O 176.1201, found 176.1195.

Deuterated 2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (d_1 -3a). Pale yellow oil; (30 mg, 54%); ¹H NMR (400 MHz, CDCl₃) δ 9.87 (s, 0.58 H), 6.29 (s, 1 H), 2.87 (t, J = 6.0 Hz, 2 H), 2.47 (t, J = 5.6 Hz, 2 H), 1.72–1.63 (m, 4 H), 1.22 (s, 6 H); ¹³C NMR (150 MHz, CDCl₃) δ 183.8, 183.5 (t, J = 102 Hz), 160.6, 151.1, 145.4, 139.3, 51.1, 24.7, 24.0, 22.8, 22.4, 21.8; HRMS calcd for $C_{12}H_{16}O$ 176.1201, found 176.1206, 177.1268.

2-Ethyl-2-methyl-4,5,6,7-tetrahydro-2*H***-indene-1-carbaldehyde (3b).** Yellow oil; (36 mg, 60%); 1 H NMR (400 MHz, CDCl₃) δ 9.85 (s, 1 H), 6.27 (s, 1 H), 2.88 (t, J = 5.6 Hz, 2 H), 2.48 (t, J = 5.2 Hz, 2 H), 1.78 (q, J = 7.2 Hz, 2 H), 1.71–1.64 (m, 4 H), 1.21 (s, 3 H),

0.57 (td, J = 7.2 Hz, 0.8 Hz, 3 H); 13 C NMR (100 MHz, CDCl₃) δ 183.7, 161.8, 149.2, 144.4, 140.6, 55.5, 28.8, 24.7, 24.0, 22.9, 22.5, 20.6, 9.4; HRMS calcd for $C_{13}H_{18}O$ 190.1358, found 190.1364.

4′,5′,6′,7′-Tetrahydrospiro[cyclopentane-1,2′-indene]-1′-carbaldehyde (3c). Yellow oil; (36 mg, 67%); 1 H NMR (400 MHz, CDCl₃) δ 9.85 (s, 1 H), 6.50 (s, 1 H), 2.87 (t, J = 6.0 Hz, 2 H), 2.46 (t, J = 6.0 Hz, 2 H), 2.20–2.13 (m, 2 H), 1.98–1.93 (m, 2 H), 1.80–1.62 (m, 6 H), 1.45–1.41 (m, 2 H); 13 C NMR (100 MHz, CDCl₃) δ 183.7, 161.6, 148.4, 142.7, 139.0, 61.7, 32.4, 26.2, 24.8, 24.1, 22.9, 22.4; HRMS calcd for C₁₄H₁₈O 202.1358, found 202.1350.

4′,5′,6′,7′-Tetrahydrospiro[cyclohexane-1,2′-indene]-1′-carbaldehyde (3d). Pale yellow solid; (40 mg, 75%); 1 H NMR (400 MHz, CDCl₃) δ 9.84 (s, 1 H), 6.92 (s, 1 H), 2.84 (t, J = 6.0 Hz, 2 H), 2.47 (t, J = 5.6 Hz, 2 H), 2.15 (td, J = 12.8, 3.2 Hz, 2 H), 1.76–1.61 (m, 6 H), 1.48–1.33 (m, 4 H), 1.05–1.02 (m, 2 H); 13 C NMR (100 MHz, CDCl₃) δ 184.0, 160.7, 146.8, 145.6, 140.8, 56.1, 31.4, 25.6, 25.0, 24.9, 24.1, 22.8, 22.4; HRMS calcd for C₁₅H₂₀O 216.1514, found 216.1512.

2-Methyl-2-phenyl-4,5,6,7-tetrahydro-2*H***-indene-1-carbaldehyde (3e).** Yellow oil; (29 mg, 39%); ¹H NMR (400 MHz, CDCl₃) δ 9.85 (s, 1 H), 7.23–7.12 (m, 5 H), 6.44 (s, 1 H), 3.03–2.88 (m, 2 H), 2.54–2.52 (m, 2 H), 1.78–1.68 (m, 4 H), 1.65 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 183.6, 161.6, 150.2, 146.0, 140.2, 139.9, 128.2, 126.3, 125.9, 57.6, 24.7, 24.3, 22.8, 22.4, 20.1; HRMS calcd for C₁₇H₁₈O 238.1358, found 238.1355.

2,2,6,6-Tetramethyl-4,5,6,7-tetrahydro-2*H***-indene-1-carbaldehyde (3f).** Yellow oil; (29 mg, 54%); 1 H NMR (400 MHz, CDCl₃) δ 9.83 (s, 1 H), 6.31 (s, 1 H), 2.60 (s, 2 H), 2.50 (td, J = 6.8, 1.2 Hz, 2 H), 1.49 (t, J = 6.8 Hz, 2 H), 1.21 (s, 6 H), 0.96 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 183.8, 160.9, 151.3, 146.1, 138.0, 51.7, 37.7, 35.4, 29.8, 28.0, 21.9, 20.8; HRMS calcd for C₁₄H₂₀O 204.1514, found 204.1507.

5-(tert-Butyl)-2,2-dimethyl-4,5,6,7-tetrahydro-2*H***-indene-1-carbaldehyde (3g).** Yellow oil; (37 mg, 69%); ¹H NMR (400 MHz, CDCl₃) δ 9.84 (s, 1 H), 6.28 (s, 1 H), 3.21 (ddd, J = 18.4, 4.4, 2.4 Hz, 1 H), 2.68–2.62 (m, 1 H), 2.53 (ddd, J = 18.4, 12.4, 5.2 Hz, 1 H), 2.07 (ddd, J = 16.4, 12.4, 2.4 Hz, 1 H), 1.98–1.92 (m, 1 H), 1.28 (ddd, J = 12.4, 4.4, 1.6 Hz, 1 H), 1.31 (s, 3 H), 1.20–1.16 (m, 4 H), 0.89 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃) δ 183.8, 160.7, 151.3, 145.0, 140.5, 51.5, 45.1, 32.4, 27.2, 26.2, 24.5, 24.1, 21.8 (2 × CH₃); HRMS calcd for C₁₆H₂₄O 232.1827, found 232.1815.

2,2-Dimethyl-4,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde (3h). Yellow oil; (35 mg, 64%); 1 H NMR (400 MHz, CDCl₃) δ 10.20 (s,1 H), 7.69 (dd, J = 6.0, 2.0 Hz, 1 H), 7.37–7.33 (m, 1 H), 7.31–7.28 (m, 2 H), 6.38 (s, 1 H), 2.84 (t, J = 6.0 Hz, 2 H), 2.59–2.55 (m, 2 H), 1.35 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 185.9, 153.0, 148.2, 144.9, 140.8, 140.2, 130.2, 130.0 (2 × CH), 128.9, 126.9, 52.8, 30.6, 23.8, 22.4; HRMS calcd for $C_{16}H_{16}O$ 224.1201, found 224.1198.

2,2-Dimethyl-2,4,5,6,7,8-hexahydroazulene-1-carbaldehyde (3i). Yellow oil; (44 mg, 80%); $^1{\rm H}$ NMR (400 MHz, CDCl₃) δ 9.86 (s, 1 H), 6.24 (s, 1 H), 2.77 (br, 2 H), 2.41–2.39 (m, 2 H), 1.72–1.70 (m, 2 H), 1.65–1.62 (m, 2 H), 1.57–1.54 (m, 2 H), 1.20 (s 6 H); $^{13}{\rm C}$ NMR (100 MHz, CDCl₃) δ 184.0, 165.5, 151.2, 146.0, 145.4, 50.8, 32.2, 30.1, 29.4, 28.7, 27.0, 21.8; HRMS calcd for C $_{13}{\rm H}_{18}{\rm O}$ 190.1358, found 190.1361.

3,5,5-Trimethyl-2-phenylcyclopenta-1,3-dienecarbaldehyde (3j). Yellow oil; (37 mg, 68%); 1 H NMR (400 MHz, CDCl₃) δ 9.49 (s, 1 H), 7.42–7.39 (m, 3 H), 7.30–7.28 (m, 2 H), 6.43 (s, 1 H), 1.85 (s, 3 H), 1.32 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 187.0, 162.4, 152.6, 148.6, 138.0, 133.0, 129.3, 128.6, 128.2, 51.0, 21.7, 13.8; HRMS calcd for C₁₅H₁₆O 212.1201, found 212.1205.

N-((2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)-methylene)-4-methylbenzenesulfonamide (7a). Orange red oil; (86 mg, 84%); ¹H NMR (400 MHz, CDCl₃) δ 8.79 (s, 1 H), 7.81 (d, J = 8.4 Hz, 2 H), 7.27 (d, J = 8.4 Hz, 2 H), 6.45 (s, 1 H), 2.79 (t, J = 6.0 Hz, 2 H), 2.46 (t, J = 5.6 Hz, 2 H), 2.39 (s, 3 H), 1.73–1.63 (m, 4 H), 1.19 (s, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 165.4, 158.8, 154.4, 143.3, 142.1, 140.2, 137.2, 129.4, 127.2, 51.6, 24.8, 24.5, 22.7, 22.2, 21.9, 21.5; HRMS calcd for C₁₀H₂₃NO₂S 329.1449, found 329.1447.

N-((2-Ethyl-2-methyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)-methylene)-4-methylbenzenesulfonamide (7b). Orange red oil; (61 mg, 57%); 1 H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 7.80 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 6.43 (s, 1 H), 2.80 (t, J = 6.4 Hz, 2 H), 2.47 (t, J = 6.4 Hz, 2 H), 2.39 (s, 3 H), 1.78 (q, J = 7.2 Hz, 2 H), 1.71–1.65 (m, 4 H), 1.17 (s, 3 H), 0.46 (t, J = 7.2 Hz, 3 H); 13 C NMR (100 MHz, CDCl₃) δ 166.6, 158.9, 152.7, 143.3, 141.6, 140.9, 137.2, 129.4, 127.1, 56.1, 28.9, 24.8, 24.5, 22.7, 22.2, 21.5, 20.8, 9.2; HRMS calcd for C₂₀H₂₅NO₂S 343.1606, found 343.1608.

4-Methyl-*N***-**((4′,5′,6′,7′-tetrahydrospiro[cyclopentane-1,2′-inden]-1′-yl)methylene)benzenesulfonamide (7c). Orange red oil; (72 mg, 65%); ¹H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1 H), 7.80 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 6.67 (s, 1 H), 2.81 (t, J = 6.0 Hz, 2 H), 2.46 (t, J = 5.6 Hz, 2 H), 2.39 (s, 3 H), 2.19–2.12 (m, 2 H), 1.98–1.90 (m, 2 H), 1.75–1.65 (m, 6 H), 1.42–1.37 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.4, 158.7, 152.1, 143.3, 140.0, 139.5, 137.3, 129.4, 127.2, 62.1, 32.8, 26.2, 24.9, 24.6, 22.8, 22.2, 21.5; HRMS calcd for C₂₁H₂₅NO₂S 355.1606, found 355.1607.

4-Methyl-*N*-((4′,5′,6′,7′-tetrahydrospiro[cyclohexane-1,2′-inden]-1′-yl)methylene)benzenesulfonamide (7d). Orange red oil; (88 mg, 76%); 1 H NMR (400 MHz, CDCl₃) δ 8.77 (s, 1 H), 7.81 (d, J = 7.6 Hz, 2 H), 7.28 (d, J = 7.6 Hz, 2 H), 7.09 (s, 1 H), 2.78 (t, J = 6.0 Hz, 2 H), 2.48 (t, J = 6.0 Hz, 2 H), 2.40 (s, 3 H), 2.20 (td, J = 13.2 Hz, 3.2 Hz, 2 H), 1.76–1.65 (m, 6 H), 1.48–1.30 (m, 4 H), 0.98 (d, J = 13.2 Hz, 2 H); 13 C NMR (100 MHz, CDCl₃) δ165.1, 159.1, 150.6, 143.3, 142.3, 141.7, 137.1, 129.4, 127.2, 56.7, 31.5, 25.5, 24.9, 24.8, 24.7, 22.7, 22.2, 21.5; HRMS calcd for $C_{22}H_{27}NO_2S$ 369.1762, found 369.1770.

4-Methyl-N-((2-methyl-2-phenyl-4,5,6,7-tetrahydro-2*H***-inden-1-yl)methylene)benzenesulfonamide (7e).** Orange red oil; (78 mg, 64%); ¹H NMR (400 MHz, CDCl₃) δ 8.75 (s, 1 H), 7.43 (d, J = 8.4 Hz, 2 H), 7.11 (d, J = 8.4 Hz, 2 H), 7.08–7.07 (m, 3 H), 7.03–7.01 (m, 2 H), 6.58 (s, 1 H), 2.95–2.80 (m, 2 H), 2.54–2.52 (m, 2 H), 2.35 (s, 3 H), 1.75–1.69 (m, 4 H), 1.67 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.2, 159.0, 153.2, 143.2, 142.9, 141.1, 139.3, 137.2, 129.1, 128.0, 126.7, 126.2, 126.1, 58.1, 25.1, 24.6, 22.7, 22.2, 21.4, 20.0; HRMS (ESI (+)) $C_{24}H_{25}NO_{25}$, calcd 391.1606 [M], found 391.1606.

4-Methyl-*N***-((2,2,6,6-tetramethyl-4,5,6,7-tetrahydro-2***H***-inden-1-yl)methylene)benzenesulfonamide (7f).** Orange red oil; (78 mg, 70%); 1 H NMR (400 MHz, CDCl₃) δ 8.79 (s, 1 H), 7.83 (d, J = 8.0 Hz, 2 H), 7.27 (d, J = 8.0 Hz, 2 H), 6.48 (s, 1 H), 2.54 (s, 2 H), 2.51 (t, J = 6.8 Hz, 2 H), 2.40 (s, 3 H), 1.50 (t, J = 6.8 Hz, 2 H), 1.19 (s, 6 H), 0.96 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 165.9, 158.8, 154.7, 143.3, 142.7, 138.9, 137.4, 129.4, 127.2, 52.2, 38.4, 35.3, 29.9, 27.9, 22.0, 21.5, 20.7; HRMS calcd for C₂₁H₂₇NO₂S 357.1762, found 357.1761.

N-((5-(tert-Butyl)-2,2-dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)-4-methylbenzenesulfonamide (7g). Orange red oil; (87 mg, 72%); 1 H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1 H), 7.82 (d, J = 8.0 Hz, 2 H), 7.27 (d, J = 8.0 Hz, 2 H), 6.46 (s, 1 H), 3.14–3.09 (m, 1 H), 2.67–2.63 (m, 1 H), 2.54–2.45 (m, 1 H), 2.40 (s, 3 H), 2.12–2.05 (m, 1 H), 2.01–1.97 (m, 1 H), 1.36–1.27 (m, 2 H), 1.20 (s, 3 H), 1.18 (s, 3 H), 0.90 (s, 9 H); 13 C NMR (100 MHz, CDCl₃) δ 165.5, 158.8, 154.6, 143.3, 141.7, 141.4, 137.2, 129.4, 127.2, 52.0, 45.0, 32.4, 27.2, 26.0, 25.3, 23.8, 22.0, 21.9, 21.5; HRMS calcd for C₂₃H₃₁NO₂S 385.2075, found 385.2070.

N-((2,2-Dimethyl-4,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-yl)methylene)-4-methylbenzenesulfonamide (7h). Orange red oil; (78 mg, 66%); ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1 H), 7.84 (d, J = 8.4 Hz, 2 H), 7.56 (d, J = 7.2 Hz, 1 H), 7.38–7.33 (m, 2 H), 7.31–7.28 (m,3 H), 6.50 (s, 1 H), 2.82 (t, J = 6.0 Hz, 2 H), 2.59–2.55 (m, 2 H), 2.41 (s, 3 H), 1.31 (s, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 157.0, 151.0, 143.5, 141.0, 140.8 (2 × C), 136.8, 130.5, 130.1, 129.5, 129.4, 129.0, 127.4 (2 × CH), 53.2, 30.4, 23.7, 22.5, 21.5; HRMS calcd for C₂₃H₂₃NO₂S 377.1449, found 377.1447.

N-((2,2-Dimethyl-2,4,5,6,7,8-hexahydroazulen-1-yl)methylene)-4-methylbenzenesulfonamide (7i). Orange red oil; (80 mg, 75%); ¹H NMR (400 MHz, CDCl₃) δ 8.86 (s, 1 H), 7.82 (d, J = 8.4 Hz, 2 H), 7.27 (d, J = 8.4 Hz, 2 H), 6.41 (s, 1 H), 2.73–2.71 (m, 2 H), 2.44–2.41 (m, 2 H), 2.40 (s, 3 H), 1.75–1.72 (m, 2 H), 1.64–1.63

(m,2 H), 1.57–1.55 (m,2 H), 1.19 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 170.3, 159.3, 154.3, 146.0, 143.3, 142.3, 137.2, 129.4, 127.2, 51.2, 32.1, 30.0, 29.2, 28.5, 28.1, 21.9, 21.5; HRMS calcd for $C_{20}H_{25}NO_2S$ 343.1606, found 343.1609.

4-Methyl-*N*-((3,5,5-trimethyl-2-phenylcyclopenta-1,3-dien-1-yl)methylene)benzenesulfonamide (7j). Orange red solid; (82 mg, 72%); 1 H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1 H), 7.77 (d, J = 8.4 Hz, 2 H), 7.43–7.42 (m, 3 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.20–7.18 (m, 2 H), 6.56 (s, 1 H), 2.39 (s, 3 H), 1.87 (s, 3 H), 1.29 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 166.1, 162.0, 155.6, 145.0, 143.5, 138.7, 136.6, 132.7, 129.4, 129.0 (2 × CH), 128.5, 127.4, 51.5, 21.9, 21.5, 13.9; HRMS calcd for $C_{22}H_{23}NO_2S$ 365.1449, found 365.1444.

N-((2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methyl)-4-methylbenzenesulfonamide (8a). Pale yellow solid; (58 mg, 67%); 1 H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 8.4 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 5.73 (s, 1 H), 3.97 (br, 1 H), 3.65 (d, J = 5.2 Hz, 2 H), 2.43 (s, 3 H), 2.35–2.34 (m, 2 H), 2.18 (br, 2 H), 1.53–1.51 (m, 4 H), 0.98 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 143.3, 140.2, 139.5, 138.4, 136.5, 129.6 (2 × CH), 127.2, 51.5, 37.8, 25.3, 23.5, 23.4, 23.2, 22.2, 21.5; HRMS calcd for $C_{19}H_{25}NO_2S$ 331.1606, found 331.1602.

3,3-Dimethyl-5,6,7,8-tetrahydro-3*H*-isochromene-1-carbaldehyde (9). Yellow oil; (23 mg, 39%); 1 H NMR (400 MHz, CDCl₃) δ 9.78 (s, 1 H), 5.35 (s, 1 H), 2.74 (t, J = 6.0 Hz, 2 H), 2.28 (t, J = 6.0 Hz, 2 H), 1.67–1.56 (m, 4 H), 1.31 (s, 6 H); 13 C NMR (100 MHz, CDCl₃) δ 184.4, 149.2, 142.9, 131.1, 129.4, 75.2, 29.1, 26.7, 23.3, 23.0, 22.8; HRMS calcd for C_{12} H₁₆ O_{2} : 192.1150, found 192.1147.

1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((2-(2-methylprop-1-en-1-yl) cyclohex-1-en-1-yl)ethynyl)gold (10). White solid; (61 mg, 68%); 1 H NMR (600 MHz, CDCl₃) δ 7.44 (t, J = 7.8 Hz, 2 H), 7.24 (d, J = 7.8 Hz, 4 H), 7.08 (s, 2 H), 5.96 (s, 1 H), 2.59–2.55 (m, 4 H), 2.10–2.08 (m, 4 H), 1.62 (s, 3 H), 1.58 (s, 3 H), 1.45–1.44 (m, 4 H), 1.33 (d, J = 7.2 Hz, 12 H), 1.18 (d, J = 7.2 Hz, 12 H); 13 C NMR (150 MHz, CDCl₃) δ 191.7, 145.7, 138.9, 134.4, 132.7, 131.6, 130.4, 127.1, 124.1, 123.0, 118.8, 105.6, 31.5, 30.0, 28.8, 27.0, 24.5, 24.0, 22.9, 22.7, 20.7; HRMS calcd for $C_{39}H_{51}$ AuN₂: 744.3718, found 744.3712.

1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((5,5-dimethyl-2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (11). Pale yellow solid; (84 mg, 68%); 1 H NMR (600 MHz, CDCl₃) δ 7.44 (t, J = 7.8 Hz, 2 H), 7.24 (d, J = 7.8 Hz, 4 H), 7.08 (s, 2 H), 5.95 (s, 1 H), 2.59–2.55 (m, 4 H), 2.10 (t, J = 6.6 Hz, 2 H), 1.90 (s, 2 H), 1.63 (s, 3 H), 1.59 (s, 3 H), 1.33 (d, J = 7.2 Hz, 12 H), 1.21 (t, J = 6.6 Hz, 2 H), 1.18 (d, J = 7.2 Hz, 12 H), 0.78 (s, 6 H); 13 C NMR (150 MHz, CDCl₃) δ 191.7, 145.6, 137.2, 134.4, 132.9, 131.1, 130.3, 126.6, 124.1, 123.0, 118.0, 105.8, 45.1, 35.6, 28.8, 28.7, 28.0, 27.5, 27.0, 24.5, 24.0, 20.7; HRMS (ESI (+)) $C_{41}H_{56}AuN_{2}^{+}$, calcd 773.4104 [M + H] $^{+}$, found 773.4128.

(3,5-Dichloropyridin-1-ium-1-yl)((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)amide (12). Yellow oil; (7 mg, 7%); 1 H NMR (600 MHz, CDCl₃) δ 8.32 (s, 1 H), 7.05 (d, J = 1.2 Hz, 1 H), 6.64 (d, J = 0.6 Hz, 1 H), 5.80 (s, 1 H), 2.59–2.56 (m, 2 H), 2.19–2.18 (m, 2 H), 1.77–1.67 (m, 7 H), 1.43 (s, 3 H); 13 C NMR (150 MHz, CDCl₃) δ 156.5, 137.9, 137.3, 133.6, 126.7, 125.6, 125.1, 123.5, 123.2, 117.6, 97.7, 31.5, 28.7, 25.6, 22.9, 22.7, 19.3; HRMS calcd for $C_{17}H_{18}Cl_2N_2$ 320.0847, found 320.0854.

ASSOCIATED CONTENT

S Supporting Information

HRMS 1 H and 13 C NMR spectra of compounds d_{1} -2a, 3a-3j, d_{1} -3a, 7a-7j, 8a, 9, 10, 11, and 12, and crystallographic data for compound 8a. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: rsliu@mx.nthu.edu.tw.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank National Science Council, Taiwan, for financial support of this work.

REFERENCES

(1) Review: Xiao, J.; Li, X. Angew. Chem., Int. Ed. 2011, 50, 7226.

(2) Selected examples: (a) Lu, B.; Li, C.; Zhang, L. J. Am. Chem. Soc. 2011, 132, 14070. (b) Vasu, D.; Hung, H.-H.; Bhunia, S.; Gawade, S. A.; Das, A.; Liu, R.-S. Angew. Chem., Int. Ed. 2011, 50, 6911. (c) He, W.; Li, C.; Zhang, L. J. Am. Chem. Soc. 2011, 133, 8482. (d) Davies, P. W.; Cremonesi, A.; Martin, N. Chem. Commun. 2011, 47, 379. (e) Dateer, R.-B.; Pati, K.; Liu, R.-S. Chem. Commun. 2012, 48, 7200. (f) Bhunia, S.; Ghorpade, S.; Huple, D. B.; Liu, R.-S. Angew. Chem., Int. Ed. 2012, 51, 2939. (g) Luo, Y.; Ji, K.; Li, Y.; Zhang, L. J. Am. Chem. Soc. 2012, 134, 17412. (h) Ghorpade, S.; Su, M.-D.; Liu, R.-S. Angew. Chem., Int. Ed. 2013, 52, 4229. (i) Fu, J.; Shang, H.; Wang, Z.; Chang, L.; Shao, W.; Yang, Z.; Tang, Y. Angew. Chem., Int. Ed. 2013, 52, 4198. (j) Henrion, G.; Chavas, T. E. J.; Goff, X. L.; Gagosz, F. Angew. Chem., Int. Ed. 2013, 52, 6277. (k) Pawar, S. K.; Wang, C.-D.; Bhunia, S.; Jadhav, A. M.; Liu, R.-S. Angew, Chem. Int. Ed. 2013, 52, 7559.

(3) For other pyridine N-oxides, see selected examples: (a) Ye, L.; Cui, L.; Zhang, G.; Zhang, L. J. Am. Chem. Soc. 2010, 132, 3258. (b) Ye, L.; He, W.; Zhang, L. J. Am. Chem. Soc. 2010, 132, 8550. (c) Ye, L.; He, W.; Zhang, L. Angew. Chem., Int. Ed. 2011, 50, 3236. (4) (a) Witham, C. A.; Mauleón, P.; Shapiro, N. D.; Sherry, B. D.; Toste, F. D. J. Am. Chem. Soc. 2007, 129, 5838. (b) Morimoto, T.; Fuji, K.; Tsutsumi, K.; Kakiuchi, K. J. Am. Chem. Soc. 2002, 124, 3806.

(5) For 6-phenyl-substituted substrates, we envisage that their resulting carbene intermediates are prone to a loss of proton, giving chemically reactive fulvene products:

$$\begin{array}{c|c} Ph & 5 \mod \% \\ \hline IPrAuNTf_2 & H \\ \hline \end{array}$$

(6) Li, C.; Zhang, L. Org. Lett. 2011, 13, 1738.

(7) Hung, H.-H.; Liao, Y.-C.; Liu, R.-S. Adv. Synth. Catal. 2013, 355, 1545.

(8) X-ray crystallographic data were deposited at Cambridged Crystallographic Data Center (CCDC 939601).

(9) A double oxidation of terminal alkynes was reported by Hashmi and coworkers; see: Shi, S.; Wang, T.; Yang, W.; Rudolph, M.; Hashmi, A. S. K. Chem.—Eur. J. 2013, 19, 6576.

(10) Ye, L.; Wang, Y.; Aue, D. H.; Zhang, L. J. Am. Chem. Soc. 2012, 134, 31.

(11) (a) Hashmi, A. S. K.; Braun, I.; Nösel, P.; Schädlich, J.; Wieteck, M.; Rudolph, M.; Rominger, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 4456. (b) Hashmi, A. S. K.; Wieteck, M.; Braun, I.; Nösel, P.; Jongbloed, L.; Rudolph, M.; Rominger, F. *Adv. Synth. Catal.* **2012**, *354*, 555. (c) Hashmi, A. S. K.; Braun, I.; Rudolph, M.; Rominger, F. *Organometallics* **2012**, *31*, 64.

(12) Preparation of alkynylgold complexes, see: Manbeck, G. F.; Kohler, M. C.; Porter, M. R.; Stockland, R. A., Jr. *Dalton Trans.* **2011**, 40, 12595.

(13) We postulated a mechanism to rationalize the formation of alkynylamide species 12, which involves a proton transfer from 3,5-dien-1-yne 1a to N-iminopyridium ylide to give G. In this ion pair, acetylide anion is stabilized with an electron-deficient pyridine core. An attack of the acetylide of species G at the electrophilic NHTs terminus gives intermediate H that provides a proton for the demetalation of species 11; this process is expected to give 3,5-dien-1-yne 1f and compound 11. We speculate that the poor activity of this reaction is caused by the presence of NTf- as a counteranion or alkynylamide 12 to inhibit the reaction.

(14) For gold-catalyzed oxidations of 1,*n*-enynes following path a, see ref 4a and Taduri, B. P.; Abu Sohel, S. Md.; Cheng, H.-M.; Liu, R.-S. *Chem. Commun.* **2007**, 2530.

(15) (a) Lian, J.-J.; Odedra, A.; Wu, C.-J.; Liu, R.-S. *J. Am. Chem. Soc.* **2005**, *127*, 4186. (b) Barluenga, J.; Andina, F.; Aznar, F.; Valdés, C. *Org. Lett.* **2007**, *9*, 4143.